11/28/2023 0 Comments River labs![]() ![]() The Consortium’s robotics development activities are coordinated by Multiply Labs, while the cell manufacturing process is overseen by UCSF through a sponsored research agreement. The Consortium is intended to demonstrate that this robotic technology can be deployed in clinical and commercial applications. These limiting factors hinder the ability to develop life-saving cell therapies at scale, significantly increase manufacturing costs and ultimately making them less accessible to patients who need them. Traditional manufacturing workflows can require hours of manual manipulation of cells and consumables, as well as highly skilled labor to develop cell therapy products. ![]() The goal of the multi-disciplinary Consortium is to develop and validate a cGMP-compliant robotic manufacturing system that is capable of manufacturing gene modified cell therapies at industrial scale.Ĭonsortium members recognize that automation of advanced living drugs is an industry-defining technology with broad implications for the whole cell therapy field. The Consortium members have a broad range of expertise in cell therapy manufacturing technologies. SAN FRANCISCO-( BUSINESS WIRE)-The robotic cell therapy manufacturing Consortium founded by Multiply Labs, with initial participation from UCSF and Cytiva, announced today that Thermo Fisher Scientific and Charles River Laboratories, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |